journal article·2019-12-11

Biomimetic and Self-Assembled Nanoclusters Targeting β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy

Jiaxin Liu, Jin Yan, Siqi Yan, Yubo Wang, Rui Zhang, Peng Hou, Wangxiao He, Meiju Ji

Nano Letters· Volume 19· Issue 12
Publisher page

Abstract

Immune checkpoint blockade therapies fail to induce immune response in the vast majority of cancer patients, so developing robust adjuvants for increasing tumor immune response is central for effective tumor immunotherapy. The Wnt/β-catenin pathway is a crucial oncogenic signal in relation to tumor immune evasion; however, none of the Wnt inhibitor under clinical or preclinical phases has demonstrated satisfactory specificity. Thus, new compounds or modalities that tumor specifically modulate the Wnt signal will be of great significance and value in clinical tumor immunotherapy. Herein, inspired by a natural phenomenon in cancer cells that the Achilles’ Heel of oncoprotein β-catenin, H1 helix, predisposes β-catenin to oligomerization for proteasomal degradation and can be exacerbated by carnosic acid (CA, a Wnt inhibitor), we developed a size-tuned nanocluster (CAcluster) with well-defined supramolecular nanostructure by coassembling CA and H1 peptide. With the inherent enhanced permeability and retention (EPR) effect and the designed tumor microenvironment (TME) responsiveness, the CAcluster tumor specifically suppress the Wnt/β-catenin cascade in vivo, while maintaining a highly favorable biosafety profile. More importantly, the CAcluster in vivo improved the tumor response to the PD1/PD-L1 immune checkpoint blockade in melanoma and colon cancer. This study provides new insights into the biomimetic coassembly strategy to design supramolecular nanostructured adjuvants for hazard-free Wnt suppression and synergy with tumor immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Wnt/β-catenin signaling in development and cancer · Cancer-related gene regulation · Cancer Mechanisms and Therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

Frontier Institute of Science and Technology, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, China

Ophthalmology Department, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

Department of Talent Highland, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

Center for Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

Funding

Xi?an Jiaotong University · Ministry of Human Resources and Social Security · National Natural Science Foundation of China · Shaanxi Province

References (44)

Show source-provided references
1. 10.1038/nrc323910.1038/nrc3239 ↗
2. 10.1038/nrc.2017.11710.1038/nrc.2017.117 ↗
3. 10.1038/nrc.2016.3610.1038/nrc.2016.36 ↗
4. 10.1001/jamaoncol.2017.306410.1001/jamaoncol.2017.3064 ↗
5. 10.1038/nature1440410.1038/nature14404 ↗
6. 10.1158/1078-0432.CCR-16-116310.1158/1078-0432.CCR-16-1163 ↗
7. 10.1126/scitranslmed.aak967010.1126/scitranslmed.aak9670 ↗
8. 10.1126/sciadv.aau524010.1126/sciadv.aau5240 ↗
9. 10.1073/pnas.141416711210.1073/pnas.1414167112 ↗
10. 10.1186/s40425-015-0089-610.1186/s40425-015-0089-6 ↗
11. 10.1016/j.ccell.2017.04.00310.1016/j.ccell.2017.04.003 ↗
12. 10.1016/j.ccr.2011.10.03010.1016/j.ccr.2011.10.030 ↗
13. 10.1038/emboj.2012.12610.1038/emboj.2012.126 ↗
14. 10.1038/nrd423310.1038/nrd4233 ↗
15. 10.1038/ncomms168010.1038/ncomms1680 ↗
16. 10.1158/1078-0432.CCR-09-294310.1158/1078-0432.CCR-09-2943 ↗
17. 10.1038/s41565-018-0356-z10.1038/s41565-018-0356-z ↗
18. 10.1016/j.biomaterials.2019.03.02610.1016/j.biomaterials.2019.03.026 ↗
19. 10.1002/adfm.20180773610.1002/adfm.201807736 ↗
20. 10.1021/acsnano.5b0437810.1021/acsnano.5b04378 ↗
21. 10.1039/c3cs60048c10.1039/c3cs60048c ↗
22. 10.1038/ncomms462310.1038/ncomms4623 ↗
23. 10.1002/anie.20150981010.1002/anie.201509810 ↗
24. 10.1016/j.addr.2009.06.00310.1016/j.addr.2009.06.003 ↗
25. 10.1016/j.jconrel.2011.03.01310.1016/j.jconrel.2011.03.013 ↗
26. 10.1016/j.addr.2003.07.01310.1016/j.addr.2003.07.013 ↗
27. 10.1016/j.jconrel.2011.03.02710.1016/j.jconrel.2011.03.027 ↗
28. 10.1016/j.cell.2006.10.01810.1016/j.cell.2006.10.018 ↗
29. 10.1146/annurev.cellbio.20.010403.11312610.1146/annurev.cellbio.20.010403.113126 ↗
30. 10.1016/S0092-8674(00)00192-610.1016/S0092-8674(00)00192-6 ↗
31. 10.1016/S0092-8674(00)80352-910.1016/S0092-8674(00)80352-9 ↗
32. 10.1016/j.cell.2012.05.01210.1016/j.cell.2012.05.012 ↗
33. 10.1016/j.molcel.2006.09.00110.1016/j.molcel.2006.09.001 ↗
34. 10.1038/nrm155210.1038/nrm1552 ↗
35. 10.1080/17435390.2019.157164610.1080/17435390.2019.1571646 ↗
36. 10.1021/acs.chemmater.8b0084010.1021/acs.chemmater.8b00840 ↗
37. 10.1038/ncomms265510.1038/ncomms2655 ↗
38. 10.1021/acsnano.8b0008110.1021/acsnano.8b00081 ↗
39. 10.1016/j.cell.2017.05.01610.1016/j.cell.2017.05.016 ↗
40. 10.1146/annurev.immunol.26.021607.09033110.1146/annurev.immunol.26.021607.090331 ↗
41. 10.1073/pnas.040819710210.1073/pnas.0408197102 ↗
42. 10.1038/nri.2016.8010.1038/nri.2016.80 ↗
43. 10.1021/ja513034e10.1021/ja513034e ↗
44. 10.1186/s13045-017-0471-610.1186/s13045-017-0471-6 ↗